TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05094700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-marketed Cosmetic Facial Cleanser
Description: Participants will apply non-marketed cosmetic facial cleanser on cleanse facial skin, twice daily for 4 weeks.
Study: NCT00446602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Description: Type=exact, unit=units, number=80,000, form=solution for injection, route=subcutaneous use, once every week or once every 2 weeks.
Study: NCT04988503

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coil embolization
Description: coil embolization for ruptured intracranial aneurysm with bare platinum coils or second-generation hydrogel coils

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coil embolization
Description: coil embolization for ruptured intracranial aneurysm with bare platinum coils or second-generation hydrogel coils
Study: NCT05586269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal Kit Delivery
Description: Families receive 6 weeks of healthy meal kit delivery. Meal kits come with embedded nutrition education and access to online cooking demonstrations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal Kit Delivery
Description: Families receive 6 weeks of healthy meal kit delivery. Meal kits come with embedded nutrition education and access to online cooking demonstrations.
Study: NCT06042517

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HEC - Hyperinsulinemic-Euglycemic-Clamp
Description: A constant i.v. insulin and variable glucose infusion will be used to determine insulin sensitivity of study participants.
Study: NCT04743102

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multi-points and full-thickness Biopsy
Description: Four points around the tumor site and center of the tumor site full-thickness Biopsy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: traditional cCR
Description: diginal examination, endoscopy test, rectal MRI, and serum CEA level
Study: NCT05196126

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Permament pacemaker implantation
Description: PM implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioneuroablation
Description: Biatrial, binodal CNA procedure with anatomical approach will be performed with pre- and post procedural extracardiac vagal nerve stimulation in general anesthesia.
Study: NCT05639907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: K21 Cavity cleanser
Description: K21 Cavity cleanser is rinsed over the TAD and allowed to dry. The TAD is placed where needed for orthodontic therapy following the Department of Orthodontics protocols.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol control
Description: Ethanol is rinsed over the TAD and allowed to dry. The TAD is placed where needed for orthodontic therapy following the Department of Orthodontics protocols.
Study: NCT05289635

Intervention type: PROCEDURE
Group type: OTHER
Intervention: different suture types
Description: For a wound that is deeper in nature, a mattress stitch can be placed, providing better strength. Mattress sutures can be applied as vertical or horizontal subtypes. So far, various studies have compared the effect of horizontal mattress suture (HMS) with vertical mattress suture (VMS) on wound healing in different wound. However, limited studies have evaluated the effect of the subtype of mattress sutures on the early wound healing and microcirculation changes of peri-implant soft tissues following implant surgery using Laser Doppler flowmetry. The test group use vertical mattress suture and the control group use the horizontal mattress suture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different suture types
Description: For a wound that is deeper in nature, a mattress stitch can be placed, providing better strength. Mattress sutures can be applied as vertical or horizontal subtypes. So far, various studies have compared the effect of horizontal mattress suture (HMS) with vertical mattress suture (VMS) on wound healing in different wound. However, limited studies have evaluated the effect of the subtype of mattress sutures on the early wound healing and microcirculation changes of peri-implant soft tissues following implant surgery using Laser Doppler flowmetry. The test group use vertical mattress suture and the control group use the horizontal mattress suture.
Study: NCT05243706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Intervention is given to study its' effect on vinca alkaloids induced neuropathy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diosmin/ Hesperidin
Description: Intervention is given to study its effect on vinca alkaloids induced neuropathy
Study: NCT05345340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: The 5-day rehabilitation program will consist of exercises to re-establish standard movement patterns within a multidisciplinary etiological framework, according to a validated rehabilitation protocol for FMDs. Treatment will be tailored to the needs of each patient, following general treatment principles in physiotherapy for FMDs.~Telemedicine sessions: the patient will perform specific exercises under the supervision of a qualified physiotherapist to provide feedback on the execution and adapt the treatment according to clinical changes/improvements.~Polar Vantage M devices will collect the objective measurement after the 5-day rehabilitation program (for five consecutive days), week 12 (for five consecutive days), and week 24 (for five consecutive days).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The 5-day rehabilitation program will be the same as the telemedicine group. A self-management paper log will be given to the patient at the end of the 5-day rehabilitation program. It will include goals, activity plans, and strategies to be used for retraining movements and redirecting attention. Videos stored on the patients' digital device (i.e., tablet, mobile) will include exercises demonstration and execution and strategies to retrain movements. Patients will be encouraged to perform the self-management plan at home on their own (or with their caregivers' help) which will be reported in a paper log and video recorded. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
Study: NCT04990804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Analgesic
Description: Patients will be provided a prescription for low dose opioids for 5 days postoperatively (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) to be taken every 6 hours as needed for pain. Refills may be provided (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) if requested by the patient at the providers discretion. In addition, patients will also be prescribed Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily and a muscle relaxer (Methocarbamol 750mg BID or Flexeril 5-10 mg TID) as needed for spasms. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid-Free Postoperative Pain Regimen
Description: Patients will receive no opioids. Pain will be managed with Acetaminophen 1000mg q8 hours, Ketorolac 10mg every 6 hours (for 5 days), Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily, and a muscle relaxer (Methocarbamol 750mg BID or Cyclobenzaprine 5-10 mg TID) all to be taken as scheduled for the first 2 weeks (except Ketorolac - 5 days) postoperatively as side effects permit. Other NSAIDS (Naprosyn 500 mg BID or Ibuprofen 800 mg TID) may be utilized if contraindications to Ketorolac exist. Famotidine (20mg BID) or Omeprazole (20mg daily) will be prescribed along with NSAIDS for GI prophylaxis. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
Study: NCT05000827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSMA-PET/CT
Description: In the intervention arm patients will only undergo ePLND in addition to robot-assisted radical prostatectomy (RARP) in case of suspected LNI on PSMA PET/CT (miN1), whereas ePLND will be omitted in those without PSMA positive lymph nodes (miN0).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nomogram
Description: Current standard of care includes performing extended pelvic lymph node dissection (ePLND) in all patients with primary prostate cancer and a nomogram-based risk of LNI \>5%
Study: NCT04841889

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Associated factors with decannulation
Description: All factors potentially associated with successful tracheostomy removal will be prospectively collected: severity factors related to the ICU stay, ventilatory factors, respiratory and extra-respiratory factors. Lung and diaphragm ultrasound, swallowing, muscles and functional assessment will be performed.
Study: NCT06524661

Intervention type: DEVICE
Intervention: AS-OCT after vitrectomy
Description: AS-OCT is a light based imaging technique of the anterior segment of the eye in this study it is used to measure the anterior chamber angle changes after pars plana vitrectomy.
Study: NCT05037162

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biochemistry blood test
Description: preformed on days 1-14 and day 28. Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL,

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biochemistry blood test
Description: preformed on days 1-14 and day 28. Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL,

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Biochemistry blood test
Description: preformed on days 1-14 and day 28. Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL,

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hematology blood test
Description: preformed on days 1-14 and day 28. complete CBC.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hematology blood test
Description: preformed on days 1-14 and day 28. complete CBC.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Hematology blood test
Description: preformed on days 1-14 and day 28. complete CBC.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: D-Dimer test (coagulation)
Description: performed on days 1,2,7,14 and 28.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: D-Dimer test (coagulation)
Description: performed on days 1,2,7,14 and 28.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: D-Dimer test (coagulation)
Description: performed on days 1,2,7,14 and 28.
Study: NCT04611399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR for psychoeducation and relaxation
Description: Use of specifically developed VR contents to deliver psychoeducational content on stress and anxiety (i.e., MIND-VR) and to train on relaxation techniques (i.e., The Secret Garden).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (CR)
Description: The CR Group will undergo pre- and post-protocol tests without undergoing any treatment.
Study: NCT06278441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care and White noise
Description: CG newborns underwent routine heel lancing, and no intervention was performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care and White noise
Description: CG newborns underwent routine heel lancing, and no intervention was performed.
Study: NCT05037162

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Inflammatory markers
Description: performed on days 1-7, 14 and 28. IL-6, IL-1β, IL-12, TNF α, IFN-γ

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Inflammatory markers
Description: performed on days 1-7, 14 and 28. IL-6, IL-1β, IL-12, TNF α, IFN-γ

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Inflammatory markers
Description: performed on days 1-7, 14 and 28. IL-6, IL-1β, IL-12, TNF α, IFN-γ

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital signs
Description: performed on days 1-14 and day 28. blood pressure, pulse, weight, weight, body temperature (PO), saturation, respiratory rate.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital signs
Description: performed on days 1-14 and day 28. blood pressure, pulse, weight, weight, body temperature (PO), saturation, respiratory rate.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Vital signs
Description: performed on days 1-14 and day 28. blood pressure, pulse, weight, weight, body temperature (PO), saturation, respiratory rate.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VAS scale
Description: performed on all study visits. score: 0-10 ; a higher score indicates a higher pain level.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VAS scale
Description: performed on all study visits. score: 0-10 ; a higher score indicates a higher pain level.
Study: NCT03595995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-621
Description: Monoclonal antibody by SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-621
Description: Monoclonal antibody by SC injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is a sterile, clear and colorless or slightly yellow liquid, contains the same composition as UB-621 except drug substance. It is given by SC injection.
Study: NCT05037162

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: VAS scale
Description: performed on all study visits. score: 0-10 ; a higher score indicates a higher pain level.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: WHO Ordinal Score
Description: performed on days 1,7,14 and 28. score: 0-3 ; a higher score indicates more symptoms.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: WHO Ordinal Score
Description: performed on days 1,7,14 and 28. score: 0-3 ; a higher score indicates more symptoms.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: WHO Ordinal Score
Description: performed on days 1,7,14 and 28. score: 0-3 ; a higher score indicates more symptoms.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19-Related Symptoms assessment
Description: performed on days 1,7,14,21 and 28. score: 0-3 ; a higher score indicates more symptoms.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19-Related Symptoms assessment
Description: performed on days 1,7,14,21 and 28. score: 0-3 ; a higher score indicates more symptoms.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19-Related Symptoms assessment
Description: performed on days 1,7,14,21 and 28. score: 0-3 ; a higher score indicates more symptoms.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19-Impact on Quality-of-Life Questionnaire
Description: performed on days 1,7,14,21 and 28. score: 1-5 ; a higher score indicates a lower quality of life.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19-Impact on Quality-of-Life Questionnaire
Description: performed on days 1,7,14,21 and 28. score: 1-5 ; a higher score indicates a lower quality of life.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19-Impact on Quality-of-Life Questionnaire
Description: performed on days 1,7,14,21 and 28. score: 1-5 ; a higher score indicates a lower quality of life.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POST- COVID-19 Functional Status Scale:
Description: performed on day 28. score: 0-3 ; a higher score indicates better recovery.
Study: NCT03595995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is a sterile, clear and colorless or slightly yellow liquid, contains the same composition as UB-621 except drug substance. It is given by SC injection.
Study: NCT06089551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SmofKabiven
Description: Participants will receive supplementary parenteral nutrition based on their calorie intake. The dosage will be adjusted on a daily basis depending on intake.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SmofKabiven
Description: Participants will receive supplementary parenteral nutrition based on their calorie intake. The dosage will be adjusted on a daily basis depending on intake.
Study: NCT05037162

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: performed on days 1 and 28.
Study: NCT05758636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: Before starting the EFT session, the participants were asked to identify the problem that aroused their anxiety. After the common point of the problems was determined, the ORDS level of all participants was determined. Next, the EFT session explained traditional acupressure meridian points on the head, face, neck, chest, and hands. Next, they were asked to repeat the phrase, Even though I have this feeling of stress and anxiety, I accept myself deeply and completely, while gently applying to the acupuncture points with their index and middle fingers. While using this expression, the participants hit each acupuncture area seven times. After the first round of hits accompanied by this phrase, participants were asked to abbreviate this feeling of anxiety, stress with another short phrase. The participants then repeated rounds of this process until they noticed that their anxiety had decreased
Study: NCT05037162

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: ECG
Description: performed on days 1 and 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment administration (twice a day)
Description: performed on days 1 and 2. twice a day, morning, and evening 1:1:1 ratio to study drug (CimetrA-1) (Arm 1) or study drug (CimetrA-2) or to Placebo (Arm 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment administration (twice a day)
Description: performed on days 1 and 2. twice a day, morning, and evening 1:1:1 ratio to study drug (CimetrA-1) (Arm 1) or study drug (CimetrA-2) or to Placebo (Arm 3)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment administration (twice a day)
Description: performed on days 1 and 2. twice a day, morning, and evening 1:1:1 ratio to study drug (CimetrA-1) (Arm 1) or study drug (CimetrA-2) or to Placebo (Arm 3)
Study: NCT05500755

Intervention type: DEVICE
Intervention: Implant Treatment
Description: Surgical placement of a DS Prime Taper implant and its posterior prosthesis.
Study: NCT05240690

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Derived MAK Immune Cells
Description: Intravenous drip
Study: NCT05447494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose CAN103
Description: Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose CAN103
Description: Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations.
Study: NCT04716790

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Debridement
Description: Ultrasounds debridement is performed using an SONOCA 185 device (Söring GmbH, Germany). The ultrasounds device generates an ultrasound low frequency of 25kHz and is equipped with three instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth. The ultrasounds instrument piezoelectrically transforms the electrical energy delivered from the ultrasound device into mechanical oscillations in the sonotrode tip.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Debridement
Description: Ultrasounds debridement is performed using an SONOCA 185 device (Söring GmbH, Germany). The ultrasounds device generates an ultrasound low frequency of 25kHz and is equipped with three instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth. The ultrasounds instrument piezoelectrically transforms the electrical energy delivered from the ultrasound device into mechanical oscillations in the sonotrode tip.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Conventional Treatment based on international guidelines for diabetic foot
Study: NCT05070715

Intervention type: OTHER
Intervention: Analyzing of microplastic level
Description: Blood samples will be taken from the vein of the umbilical cord. Placental tissues will be taken from the maternal side of the placenta. Placental tissues and serum samples will be stored in the temperature set to -80 °C until analysis. Extraction methods involving chemical reactions will be used to separate and purify microplastics in placenta and cord blood samples. After the extraction process, analysis of microplastic levels in tissues and serum will be done by µ-Raman spectroscopy.

Intervention type: OTHER
Intervention: Analyzing of microplastic level
Description: Blood samples will be taken from the vein of the umbilical cord. Placental tissues will be taken from the maternal side of the placenta. Placental tissues and serum samples will be stored in the temperature set to -80 °C until analysis. Extraction methods involving chemical reactions will be used to separate and purify microplastics in placenta and cord blood samples. After the extraction process, analysis of microplastic levels in tissues and serum will be done by µ-Raman spectroscopy.